Historical Valuation
Avidity Biosciences Inc (RNA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 958.74 is considered Overvalued compared with the five-year average of -7.32. The fair price of Avidity Biosciences Inc (RNA) is between 3.02 to 31.65 according to relative valuation methord. Compared to the current price of 72.37 USD , Avidity Biosciences Inc is Overvalued By 128.68%.
Relative Value
Fair Zone
3.02-31.65
Current Price：72.37
128.68%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Avidity Biosciences Inc (RNA) has a current Price-to-Book (P/B) ratio of 5.61. Compared to its 3-year average P/B ratio of 2.83 , the current P/B ratio is approximately 98.33% higher. Relative to its 5-year average P/B ratio of 2.74, the current P/B ratio is about 104.77% higher. Avidity Biosciences Inc (RNA) has a Forward Free Cash Flow (FCF) yield of approximately -5.45%. Compared to its 3-year average FCF yield of -12.47%, the current FCF yield is approximately -56.28% lower. Relative to its 5-year average FCF yield of -11.58% , the current FCF yield is about -52.93% lower.
P/B
Median3y
2.83
Median5y
2.74
FCF Yield
Median3y
-12.47
Median5y
-11.58
Competitors Valuation Multiple
AI Analysis for RNA
The average P/S ratio for RNA competitors is 163.05, providing a benchmark for relative valuation. Avidity Biosciences Inc Corp (RNA.O) exhibits a P/S ratio of 958.74, which is 488% above the industry average. Given its robust revenue growth of 434.03%, this premium appears sustainable.
Performance Decomposition
AI Analysis for RNA
1Y
3Y
5Y
Market capitalization of RNA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RNA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RNA currently overvalued or undervalued?
Avidity Biosciences Inc (RNA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 958.74 is considered Overvalued compared with the five-year average of -7.32. The fair price of Avidity Biosciences Inc (RNA) is between 3.02 to 31.65 according to relative valuation methord. Compared to the current price of 72.37 USD , Avidity Biosciences Inc is Overvalued By 128.68% .
What is Avidity Biosciences Inc (RNA) fair value?
RNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Avidity Biosciences Inc (RNA) is between 3.02 to 31.65 according to relative valuation methord.
How does RNA's valuation metrics compare to the industry average?
The average P/S ratio for RNA's competitors is 163.05, providing a benchmark for relative valuation. Avidity Biosciences Inc Corp (RNA) exhibits a P/S ratio of 958.74, which is 488.00% above the industry average. Given its robust revenue growth of 434.03%, this premium appears sustainable.
What is the current P/B ratio for Avidity Biosciences Inc (RNA) as of Jan 09 2026?
As of Jan 09 2026, Avidity Biosciences Inc (RNA) has a P/B ratio of 5.61. This indicates that the market values RNA at 5.61 times its book value.
What is the current FCF Yield for Avidity Biosciences Inc (RNA) as of Jan 09 2026?
As of Jan 09 2026, Avidity Biosciences Inc (RNA) has a FCF Yield of -5.45%. This means that for every dollar of Avidity Biosciences Inc’s market capitalization, the company generates -5.45 cents in free cash flow.
What is the current Forward P/E ratio for Avidity Biosciences Inc (RNA) as of Jan 09 2026?
As of Jan 09 2026, Avidity Biosciences Inc (RNA) has a Forward P/E ratio of -13.80. This means the market is willing to pay $-13.80 for every dollar of Avidity Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Avidity Biosciences Inc (RNA) as of Jan 09 2026?
As of Jan 09 2026, Avidity Biosciences Inc (RNA) has a Forward P/S ratio of 958.74. This means the market is valuing RNA at $958.74 for every dollar of expected revenue over the next 12 months.